Patents by Inventor M. Edward Pierson, Jr.

M. Edward Pierson, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dibenzothiazepine derivatives and uses thereof—424
    Patent number: 8653257
    Abstract: Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: February 18, 2014
    Assignee: Astrazeneca AB
    Inventors: Dean Brown, James R. Damewood, Phil Edwards, James Hulsizer, James Campbell Muir, M. Edward Pierson, Jr., Ashokkumar Bhikkappa Shenvi, Steven Wesolowski, Dan Widzowski, Michael Wood
  • DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424
    Publication number: 20120202991
    Abstract: Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.
    Type: Application
    Filed: April 12, 2012
    Publication date: August 9, 2012
    Inventors: Dean Brown, James R. Damewood, Phil Edwards, James Hulsizer, James Campbell Muir, M. Edward Pierson, JR., Ashokkumar Bhikkappa Shenvi, Steven Wesolowski, Dan Widzowski, Michael Wood
  • Dibenzothiazepine derivatives and uses thereof—424
    Patent number: 8158618
    Abstract: Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: April 17, 2012
    Assignee: AstraZeneca AB
    Inventors: Dean Brown, James R. Damewood, Phil Edwards, James Hulsizer, James Campbell Muir, M. Edward Pierson, Jr., Ashokkumar Bhikkappa Shenvi, Steven Wesolowski, Dan Widzowski, Michael Wood
  • Dibenzothiazepine Derivatives and Use Thereof
    Publication number: 20110160184
    Abstract: Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.
    Type: Application
    Filed: June 18, 2009
    Publication date: June 30, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Dean Brown, Steven Wesolowski, Dan Widzowski, James R. Damewood, M. Edward Pierson, Jr., Michael Wood, Philip Edwards, James Hulsizer, Ashokkumar Bhikkappa Shenvi, James Campbell Muir
  • DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424
    Publication number: 20090318415
    Abstract: Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.
    Type: Application
    Filed: June 19, 2009
    Publication date: December 24, 2009
    Applicant: AstraZeneca AB
    Inventors: Dean Brown, James R. Damewood, Phil Edwards, James M. Hulsizer, James Campbell Muir, M. Edward Pierson, Jr., Ashokkumar Bhikkappa Shenvi, Steven Wesolowski, Dan Widzowski, Michael Wood
  • 2-aryl dihydropyrimidine compounds
    Patent number: 6218538
    Abstract: There are provided novel compounds of formula (I) including their 3,4-dihydropyrimidine tautomer form, wherein R1, R2, R3, R4, R5, X and n are as defined in the specification, and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are antagonists of N-type neuronal calcium channels useful in the treatment of cerebrovascular ischaemia and pain.
    Type: Grant
    Filed: October 14, 1998
    Date of Patent: April 17, 2001
    Assignee: Astra Aktiebolag
    Inventors: Eileen S. Downs, William F. Michne, M. Edward Pierson, Jr.
  • Substituted 1,4-dihydropyrimidine-5-carboxylate compounds, their preparation and uses
    Patent number: 6057332
    Abstract: There are provided novel compounds of formula (I) ##STR1## including their 3,4-dihydropyrimidine tautomer form, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, X and n are as defined in the specification, and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are antagonists of N-type neuronal calcium channels useful in the treatment of cerebrovascular ischaemia and pain.
    Type: Grant
    Filed: October 14, 1998
    Date of Patent: May 2, 2000
    Assignee: Astra Aktiebolag
    Inventors: William F. Michne, M. Edward Pierson, Jr.